Bayer Rewrites the Script: Supreme Court Closes Roundup Door While Pipeline Deals Open New Ones
26.06.2026 - 13:47:38 | boerse-global.de
The two-pronged offensive Bayer has been quietly assembling finally exploded into view. Over seven trading sessions, the shares surged roughly 25% — a move that reflected not just a landmark legal victory but also a parallel push into high-growth areas of drug development. Investors who had spent years watching the stock sink under the weight of glyphosate litigation suddenly saw the pieces fall into place: a Supreme Court ruling that dismantled the biggest avenue for new Roundup claims, and a string of pipeline investments capped by a $2.45 billion ophthalmology bet.
The decision handed down by the U.S. Supreme Court on June 25, 2026, did not address whether glyphosate causes cancer. Instead it settled a fundamental preemption question — who gets to mandate warning labels in the United States. The court ruled that the federal Environmental Protection Agency has the sole authority, overriding individual states and juries in liability cases. This effectively closes the "failure-to-warn" door that had been the main gateway for tens of thousands of lawsuits. The ruling does not erase the more than $10 billion Bayer has already spent on settlements or the €11.8 billion in litigation provisions (€9.6 billion of that tied to glyphosate). But it transforms the open-ended risk into something far more quantifiable.
Simultaneously, Bayer has been rebuilding its future revenue stream. In June it completed the acquisition of Perfuse Therapeutics, gaining full rights to PER-001, a phase II intravitreal implant targeting glaucoma and diabetic retinopathy — conditions affecting up to 80 million and 146 million people worldwide, respectively. The upfront payment was $300 million, with milestone-based payments that could bring the total to $2.45 billion. PER-001 is described as a potential first-in-class small-molecule endothelin receptor antagonist implant with no direct comparator on the market. The same month, Bayer announced a research collaboration with Iambic Therapeutics, leveraging the AI platforms Enchant and NeuralPLexer to discover drug candidates against hard-to-drug targets. To that pipeline progress add the FDA approval for the contrast agent AMBELVIST in June and positive phase III data for the stroke-prevention candidate Asundexan from February. Nubeqa and Kerendia continue to deliver meaningful sales growth.
Should investors sell immediately? Or is it worth buying Bayer?
The financial repair work, however, remains messy. Bayer trimmed net debt from €32.6 billion to €29.8 billion in 2025, generating free cash flow of €2.1 billion. But 2026 will be a different story: litigation-related outflows of roughly €5 billion are expected to push free cash flow negative. The Supreme Court ruling could ease that burden over time, but the immediate cash drain is locked in. The collective settlement of $7.25 billion announced in February — covering approximately 65,000 open cases — received preliminary approval in March. Class members had until June 4 to opt out, and the final fairness hearing is set for July 9 in Missouri. Bayer has stated it aims to "significantly contain" Roundup litigation by the end of 2026, a promise that now carries genuine weight.
The stock’s technical picture reflects the intensity of the re-rating. Currently trading at €47.19, the share price sits about 88% above the 52-week low of €25.09 struck in August 2025. The relative strength index has climbed to 81.3, a level that typically signals overbought conditions, and the annualized 30-day volatility of 57.82% underscores how tightly the shares are tethered to legal headlines and deal news. The 52-week high of €49.93, reached in February, is now within striking distance if the July 9 hearing produces a final nod for the class settlement. For a company that has carried the legacy of the most expensive acquisition in German corporate history — the roughly $60 billion Monsanto takeover — the Supreme Court ruling does not erase past mistakes. But it turns an open wound into a manageable scar, and investors are pricing in the possibility that the worst is finally behind them.
Ad
Bayer Stock: New Analysis - 26 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
